Association of vaspin rs2236242 and Val109Asp omentin genes polymorphism and their serum levels with increased risk of breast cancer

Breast cancer represents the leading cause of cancer-related death in women globally. Obesity is one of the risk factors for breast cancer, particularly in postmenopausal women. Adiposopathy causes hypertrophy, which promotes metabolic dysregulation, hypoxia, inflammation, insulin resistance, and altered adipokine production such as vaspin and omentin-1. The objective of this study is to inspect the link between the vaspin rs2236242 and the Val109Asp omentin gene polymorphisms and their serum levels with breast cancer occurrence in postmenopausal females. The gene polymorphisms of vaspin rs2236242 and Val109Asp omentin were identified by T-ARMS-PCR and PCR-RFLP respectively. The glucose homeostasis traits, lipid profile, total antioxidant capacity, and circulating vaspin and omentin-1 levels were all assessed. The AT genotype of vaspin rs2236242 and the Val/Asp genotype of Val109Asp omentin were more prominent in breast cancer patients than the TT and Asp/Asp genotypes respectively. Breast cancer patients showed significant lower levels of serum vaspin and omentin-1. The AT genotype of the vaspin rs2236242 polymorphism, the heterozygous Asp/Val genotype of the omentin-1 gene, and low serum vaspin and omentin-1 levels are more associated with breast cancer incidence. On the flip side, higher levels of serum vaspin and omentin appear to protect against the incidence of breast cancer.